CA
NZ
UK
AU
IND
US
…
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Corbus Pharmaceuticals Holding is a clinical-stage biopharmaceutical company developing anti-inflammatory and immunomodulatory therapies, principally lenabasum, for chronic inflammatory and fibrotic diseases. Long-term growth drivers may include successful late-stage clinical data and regulatory approvals across indications, demonstration of meaningful clinical benefit in areas of unmet need, and partnerships or licensing to support commercialization.
Material risks include high clinical and regulatory risk, limited or no commercial revenue with attendant funding and dilution risk, and competitive pressure from other immunomodulatory and antifibrotic programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -78.54M | -40.21M | -44.60M | -42.35M | -45.64M |
| Net income | -78.54M | -40.21M | -44.60M | -55.83M | -45.55M |
| Selling general administrative | 15.21M | 16.50M | 13.91M | 18.70M | 20.43M |
| Selling and marketing expenses | - | - | 13896.37M | - | - |
| Gross profit | -0.23M | -0.60M | -0.64M | -1.49M | -0.76M |
| Reconciled depreciation | 0.23M | 0.59M | 1.40M | 1.49M | 1.64M |
| Ebit | -85.31M | -38.34M | -45.08M | -39.84M | -55.99M |
| Ebitda | -85.08M | -37.74M | -44.44M | -29.50M | -56.27M |
| Depreciation and amortization | 0.23M | 0.60M | 0.64M | 10.33M | -0.28M |
| Operating income | -85.31M | -48.72M | -45.08M | -39.84M | -55.99M |
| Other operating expenses | 85.31M | 48.72M | 45.08M | 34.84M | 56.87M |
| Interest expense | 0.00M | 1.87M | 2.92M | 2.13M | 1830.49M |
| Interest income | 5.53M | 6.31M | - | - | - |
| Net interest income | 5.53M | 4.44M | -2.86M | -2.13M | -1.83M |
| Income tax expense | - | - | - | 13.49M | -0.09M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.88M |
| Total operating expenses | 85.31M | 48.12M | 44.44M | 34.84M | 56.87M |
| Cost of revenue | 0.23M | 0.60M | 0.64M | 1.49M | 1.64M |
| Total other income expense net | 6.77M | 8.51M | 0.47M | -2.51M | 10.35M |
| Net income from continuing ops | -78.54M | -40.21M | -47.46M | -42.35M | -45.64M |
| Net income applicable to common shares | - | - | - | -42.35M | -45.64M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 168.19M | 155.88M | 28.27M | 66.31M | 107.73M |
| Other current assets | 1.51M | 3.91M | 2.45M | 0.79M | 2.37M |
| Total liab | 20.69M | 13.45M | 35.18M | 33.32M | 38.62M |
| Total stockholder equity | 147.50M | 142.43M | -6.90M | 32.99M | 69.11M |
| Other current liab | 16.84M | 5.43M | 11.07M | 6.04M | 0.13M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Retained earnings | -555.43M | -476.89M | -436.68M | -392.08M | -349.73M |
| Other liab | - | - | - | 0.02M | 0.02M |
| Other assets | - | - | 0.00M | 0.63M | 0.52M |
| Cash | 28.49M | 17.20M | 13.92M | 17.00M | 25.01M |
| Total current liabilities | 20.69M | 11.82M | 31.89M | 12.64M | 17.01M |
| Current deferred revenue | - | - | - | - | 10.09M |
| Net debt | -26.86M | -13.96M | 6.97M | 8.09M | 1.58M |
| Short term debt | 1.63M | 1.61M | 17.65M | 4.43M | 5.00M |
| Short long term debt | - | - | 16.21M | 3.15M | 3.86M |
| Short long term debt total | 1.63M | 3.24M | 20.88M | 25.09M | 26.59M |
| Other stockholder equity | 702.98M | 619.28M | 429.78M | 425.20M | 418.89M |
| Property plant equipment | - | - | - | 5.50M | 7.00M |
| Total current assets | 166.95M | 152.98M | 23.55M | 60.18M | 100.20M |
| Net tangible assets | - | - | - | 32.99M | 69.11M |
| Short term investments | 134.78M | 131.86M | 7.18M | 42.19M | 72.64M |
| Net receivables | 1.50M | - | - | - | - |
| Long term debt | - | - | - | 15.98M | 15.64M |
| Accounts payable | 2.21M | 4.79M | 3.18M | 2.17M | 1.78M |
| Accumulated other comprehensive income | -0.05M | 0.04M | -0.00M | -0.13M | -0.06M |
| Non currrent assets other | - | 0.39M | 0.21M | 0.63M | 0.52M |
| Non current assets total | 1.24M | 2.90M | 4.73M | 6.13M | 7.53M |
| Capital lease obligations | 1.63M | 3.24M | 4.68M | 5.96M | 7.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -1.63M | -121.31M | 37.03M | 30.07M | -73.39M |
| Change to liabilities | - | - | - | -0.26M | -5.96M |
| Total cashflows from investing activities | -1.64M | -121.31M | - | 30.07M | -73.42M |
| Net borrowings | 0.00M | -15.48M | - | -0.53M | 0.06M |
| Total cash from financing activities | 77.43M | 166.58M | -2.82M | -0.53M | 60.82M |
| Change to operating activities | - | - | - | -3.77M | -11.36M |
| Net income | -78.54M | -40.21M | -44.60M | -42.35M | -45.64M |
| Change in cash | 11.29M | 3.47M | -3.28M | -8.00M | -60.78M |
| Begin period cash flow | 17.87M | 14.39M | 17.20M | 25.68M | 86.45M |
| End period cash flow | 29.16M | 17.87M | 13.92M | 17.67M | 25.68M |
| Total cash from operating activities | -64.49M | -41.79M | -36.10M | -37.54M | -48.18M |
| Issuance of capital stock | 77.43M | 182.06M | 0.24M | 0.04M | 62.59M |
| Depreciation | -1.13M | -2.74M | 0.64M | 1.49M | 1.64M |
| Change to inventory | - | - | - | - | -1.62M |
| Change to account receivables | - | - | - | - | 1.62M |
| Other cashflows from financing activities | 77.43M | 166.58M | -0.00M | 1.83M | -73.42M |
| Change to netincome | - | - | - | 6.60M | 10.81M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.01M | 0.05M |
| Change in working capital | 9.12M | -5.58M | 4.09M | -4.02M | -15.70M |
| Stock based compensation | 6.29M | 6.14M | 3.47M | 5.72M | 9.48M |
| Other non cash items | -0.23M | 0.58M | 1028.58M | 1.62M | 0.95M |
| Free cash flow | -64.50M | -41.79M | -36.10M | -37.56M | -48.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holding |
- -% |
4.22 | - | - | 169.88 | 1.53 | 4531.61 | 0.17 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
500 River Ridge Drive, Norwood, MA, United States, 02062
617 963 0100
36
| Name | Title | Year Born |
|---|---|---|
| Dr. Yuval Cohen Ph.D. | CEO & Director | 1975 |
| Mr. Sean F. Moran CPA, M.B.A., CPA, MBA | Chief Financial Officer | 1958 |
| Mr. Craig Stuart Millian M.B.A. | Chief Operating Officer | 1969 |
| Dr. Rachael Brake Ph.D. | Chief Scientific Officer | 1972 |
| Ted Jenkins | Sr. Director of Investor Relations & Corp. Communications | NA |
| Ms. Lindsey Smith | Head of Corp. Communications & Patient Advocacy | NA |
| Ms. Christina Bertsch | Head of HR | NA |
| Scott Constantine | Sr. Director & Head of Clinical Operations | NA |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer | 1958 |
| Ms. Lindsey Smith | Head of Corporate Communications & Patient Advocacy | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...